Harbin Pharmaceutical Group Co (SHSE:600664) Market Cap: ¥7,782 Mil (As of Jul. 08, 2026)


SHSE:600664 Harbin Pharmaceutical Group Co Ltd SHSE:600664
73 GF Score
Price ¥3.09
GF Value ¥3.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harbin Pharmaceutical Group Co Market Cap?

Harbin Pharmaceutical Group Co SHSE:600664 +0.65% 73 Market Cap is ¥7,782 Mil as of Jul. 08, 2026. GuruFocus rates SHSE:600664 with a GF Score™ of 73/100 and a GF Value™ of ¥3.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks better than 77.05% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Harbin Pharmaceutical Group Co's share price for the quarter that ended in Mar. 2026 was ¥3.52. Harbin Pharmaceutical Group Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2,519 Mil. Therefore, Harbin Pharmaceutical Group Co's market cap for the quarter that ended in Mar. 2026 was ¥8,865 Mil.

Harbin Pharmaceutical Group Co's quarterly market cap declined from Sep. 2025 (¥8,991 Mil) to Dec. 2025 (¥8,689 Mil) but then increased from Dec. 2025 (¥8,689 Mil) to Mar. 2026 (¥8,865 Mil).

Harbin Pharmaceutical Group Co's annual market cap increased from Dec. 2023 (¥8,446 Mil) to Dec. 2024 (¥10,401 Mil) but then declined from Dec. 2024 (¥10,401 Mil) to Dec. 2025 (¥8,689 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Harbin Pharmaceutical Group Co's Enterprise Value for Today is ¥6,546 Mil.


Harbin Pharmaceutical Group Co  (SHSE:600664) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Harbin Pharmaceutical Group Co Market Cap Related Terms


Harbin Pharmaceutical Group Co Market Cap Historical Data

* Premium members only.

The historical data trend for Harbin Pharmaceutical Group Co's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Pharmaceutical Group Co Market Cap Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,940.23 7,602.89 8,446.28 10,401.45 8,688.86

Harbin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,217.75 9,268.12 8,991.08 8,688.86 8,865.16

SHSE:600664 vs ZTS, UTHR: Market Cap Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Pharmaceutical Group Co Market Cap vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Market Cap distribution charts can be found below:

* The bar in red indicates where Harbin Pharmaceutical Group Co's Market Cap falls into.


SHSE:600664
73GF Score
Harbin Pharmaceutical Group Co Ltd SHSE:600664
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harbin Pharmaceutical Group Co Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Harbin Pharmaceutical Group Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=¥3.45*2518.510
=¥8,689

Harbin Pharmaceutical Group Co's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=¥3.52*2518.510
=¥8,865

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of ¥7,782 Mil mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Market Cap of ¥7,782 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Harbin Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #235 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 22.9%.
Is Harbin Pharmaceutical Group Co's Market Cap too high?
Harbin Pharmaceutical Group Co's current Market Cap is ¥7,782 Mil. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #235 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #235 out of 1024 companies for Market Cap. This places Harbin Pharmaceutical Group Co in the top 23% of its industry — outperforming the majority of peers. The industry median Market Cap is 217.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 217.24, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 217.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current Market Cap is ¥7,782 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥3.09 — trading 12% below its estimated fair value. The current Market Cap is ¥7,782 Mil. Harbin Pharmaceutical Group Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Market Cap is ¥7,782 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?

Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥3.09 is trading 12% below its estimated GF Value™ of ¥3.51. GuruFocus considers Harbin Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:600664:

  • Market Cap: ¥7,782 Mil
  • GF Value™: ¥3.51 vs. price of ¥3.09 (12% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harbin Pharmaceutical Group Co Business Description

Address Xi\'an Street West, People \'s Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
73GF Score

Get the complete analysis for SHSE:600664

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.09
Price
¥3.51
GF Value